MIPSS70 score | MIPSS70-plus version 2.0 score

#	Question	Answer
1	Severe Anemia (hemoglobin <80g/L)	Yes No
2	Moderate Anemia (hemoglobin 80-100g/L)	Yes No
3	Leucocytosis >25x10⁹/L	Yes No
4	Thrombocytopenia (platelet count <100x10⁹/L)	Yes No
5	Peripheral blood blast count ≥2%	Yes No
6	Bone marrow fibrosis grade ≥2	Yes No
7	Constitutional symptoms	Yes No
8	Absence of CALR type 1/like mutation	Yes No
9	HMR¹ category	Yes No
10	≥2 HMR mutated genes	Yes No
11	Unfavorable karyotype²	Yes No Not available
12	Very High Risk karyotype³	Yes No Not available

	Score	Result
	MIPSS70	LOW RISK [5-year OS= 96%] INTERMEDIATE RISK [5-year OS= 67%] HIGH RISK [5-year OS= 34%]
	MIPSS70-plus version 2.0	VERY LOW RISK [10-year OS= 92%] LOW RISK [10-year OS= 56%] INTERMEDIATE RISK [10-year OS= 37%] HIGH RISK [10-year OS= 13%] VERY HIGH RISK [10-year OS< 5%] NOT AVAILABLE

* presence of at least one mutated gene among ASXL1, EZH2, SRSF2, IDH1/2

Vannucchi AM, Lasho TL, Guglielmelli P, et al: Mutations and prognosis in primary myelofibrosis. Leukemia 27:1861-9, 2013

¹ HMR for MIPSS70+ version 2.0 included also mutation in U2AF1 gene.

Tefferi A et al: MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. JCO 36, no. 17 :1769-1770, 2018

² indicates any abnormal karyotype other than normal karyotype or sole abnormalities of 20q-, 13q-, +9, chromosome 1 translocation/duplication, -Y or sex chromosome abnormality other than –Y

Tefferi A et al. Revised cytogenetic risk stratification in primary myelofibrosis. 2017; under submission.

³ single/multiple abnormalities of -7, i(17q), inv(3)/3q21, 12p-/12p11.2, 11q-/11q23, or other autosomal trisomies not including + 8/ + 9 (e.g., +21, +19); ‘Favorable‘:normal karyotype or sole abnormalities of 13q-, +9, 20q-, chromosome 1 translocation/duplication or sex chromosome abnormality including -Y; ‘Unfavorable‘: all other abnormalities.(Ref 3)

Tefferi A et al:Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. Leukemia. 2018 May;32(5):1189-1199.